TG Therapeutics (NASDAQ:TGTX) is a biopharmaceutical company dedicated to developing and commercializing novel treatments for B-cell cancers and autoimmune diseases. Headquartered in New York, TG Therapeutics focuses on targeted therapies that leverage monoclonal antibodies and small-molecule inhibitors to address critical unmet medical needs. The company’s research and development efforts center on combination approaches designed to improve patient outcomes by attacking disease through complementary mechanisms of action.
The company’s two lead products, ublituximab and umbralisib, have secured regulatory approval for indications in hematologic malignancies. Ublituximab is a glycoengineered anti-CD20 monoclonal antibody, while umbralisib is an oral PI3K delta inhibitor. These agents are marketed for the treatment of relapsed or refractory chronic lymphocytic leukemia, marginal zone lymphoma and follicular lymphoma. Beyond these approved therapies, TG Therapeutics maintains a diversified pipeline, which includes novel compounds such as TG-1701 (a Bruton’s tyrosine kinase inhibitor) and early-stage programs aimed at expanding into multiple sclerosis and other immune-mediated conditions.
Founded in 2007, TG Therapeutics has grown through strategic collaborations and acquisitions. The company has entered into partnerships with academic centers and biotechnology firms to accelerate development and optimize commercial strategies. While its primary market is the United States, TG Therapeutics is pursuing regulatory filings and distribution agreements in Europe, Canada and parts of Asia, laying the groundwork for broader global reach.
Leadership at TG Therapeutics is led by Chairman and Chief Executive Officer Michael S. Weiss, who co-founded the company and has overseen its transition from early-stage research to commercial operations. The executive team brings together expertise in oncology, immunology and specialty pharmaceuticals, supported by a board of directors with deep experience in drug development and market commercialization. Together, they guide TG Therapeutics’ mission to bring innovative therapies to patients suffering from B-cell malignancies and autoimmune disorders.
